Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
- PMID: 12794167
- DOI: 10.4049/jimmunol.170.12.6338
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
Abstract
CD8(+) CTL play important roles against malignancy in both active and passive immunotherapy. Nonetheless, the success of antitumor CTL responses may be improved by additional therapeutic modalities. Radiotherapy, which has a long-standing use in treating neoplastic disease, has been found to induce unique biologic alterations in cancer cells affecting Fas gene expression, which, consequently, may influence the overall lytic efficiency of CTL. Here, in a mouse adenocarcinoma cell model, we examined whether exposure of these tumor cells to sublethal doses of irradiation 1) enhances Fas expression, leading to more efficient CTL killing via Fas-dependent mechanisms in vitro; and 2) improves antitumor activity in vivo by adoptive transfer of these Ag-specific CTL. Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells with irradiation (20 Gy) in vitro enhanced Fas expression at molecular, phenotypic, and functional levels. Furthermore, irradiation sensitized these targets to Ag-specific CTL killing via the Fas/Fas ligand pathway. We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry. Moreover, localized irradiation of the tumor significantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL. Overall, these results showed for the first time that 1) regulation of the Fas pathway in tumor cells by irradiation plays an important role in their sensitization to Ag-specific CTL; and 2) a combination regimen of tumor-targeted irradiation and CTL promotes more effective antitumor responses in vivo, which may have implications for the combination of immunotherapy and radiation therapy.
Similar articles
-
The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.J Immunol. 2003 Sep 1;171(5):2402-12. doi: 10.4049/jimmunol.171.5.2402. J Immunol. 2003. PMID: 12928387
-
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.J Immunol. 2002 Apr 1;168(7):3484-92. doi: 10.4049/jimmunol.168.7.3484. J Immunol. 2002. PMID: 11907109
-
Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.J Immunol. 2000 May 1;164(9):4941-54. doi: 10.4049/jimmunol.164.9.4941. J Immunol. 2000. PMID: 10779805
-
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
-
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.Front Immunol. 2018 Jan 22;9:14. doi: 10.3389/fimmu.2018.00014. eCollection 2018. Front Immunol. 2018. PMID: 29403496 Free PMC article. Review.
Cited by
-
Clinical development of Listeria monocytogenes-based immunotherapies.Semin Oncol. 2012 Jun;39(3):311-22. doi: 10.1053/j.seminoncol.2012.02.008. Semin Oncol. 2012. PMID: 22595054 Free PMC article. Review.
-
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.Int J Mol Sci. 2023 Nov 26;24(23):16773. doi: 10.3390/ijms242316773. Int J Mol Sci. 2023. PMID: 38069095 Free PMC article. Review.
-
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.Oncology (Williston Park). 2015 May;29(5):331-40. Oncology (Williston Park). 2015. PMID: 25979541 Free PMC article. Review.
-
Emerging Treatment Paradigms in Radiation Oncology.Clin Cancer Res. 2015 Aug 1;21(15):3393-401. doi: 10.1158/1078-0432.CCR-14-1191. Epub 2015 May 19. Clin Cancer Res. 2015. PMID: 25991820 Free PMC article. Review.
-
A 'Hybrid' Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy.Cancers (Basel). 2022 Jul 19;14(14):3505. doi: 10.3390/cancers14143505. Cancers (Basel). 2022. PMID: 35884565 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous